



RADIATION SAFETY OFFICE
UNIVERSITY OF MISSOURI
413 CLARK
COLUMBIA, MISSOURI 65211
314-882-3721

PDR

~~Deso~~

Date 10/16/81

TO: Allen Brodsky

Attached is a more complete set of documents on bioassay for tritium than sent to you previously. What I sent earlier was the "final version" of the document with the original p. 18 replaced by a revised p. 18 as approved at the meeting. Included with this more complete package is the original letter of transmittal that included a history and a list of contributors amongst which was Allen Brodsky, Sc.D., of the NRC. There was also a special dedication to Leo Wade, Jr., Ph.D., for reasons left unstated but generally known.

As explained in the report, we did not try to solve all problems relating to tritium exposure. We were addressing the use of tritium in the university where circumstances of use tend to reduce the magnitude of the hazard.

John Jolan

8209230397 811016
PDR REGGD
08. XXX C

PDR

RadSafe-5



UNIVERSITY OF MISSOURI

PDR

*Houston meeting was held July 11-13, 1977;
it was the Sixth Biennial Conference of
Campus Radiation Safety Officers* Radiation Safety Office

413 Clark Hall
Columbia, Missouri 65201
Telephone: (314) 882-3721

July 28, 1977

MEMORANDUM

To: University Radiation Safety Officers

OP-713-4

Subject: Clarification of Content of Bioassay Guide for Tritium

A suggestion was made during the Houston meeting to clarify the intent of the recommendation made on page 18 of the Final Draft on Guidelines for Bioassay for Exposure to Tritium. The suggestior (from Paul Ziemer) related to the phrase "Bioassays shall be performed at least monthly . . ." on line 9 from which regulators might infer that samples are to be taken and analyzed without interruption regardless of frequency of exposure. Hoping to be the last rather than the first person to concede any leverage to the regulators, I want to remove any uncertainty about the intent of this recommendation. At the meeting, I encouraged everyone to note in the margin of their copy that this sampling frequency was intended to apply only to a period of time in which tritium was in regular use. Otherwise the procedure for "Non-routine Bioassay" on page 19 was to apply. For the benefit of those not at the meeting, I have revised page 18 in an effort to remove this ambiguity.

Other modifications on page 18 include the addition of "or other DNA precursors" to the category of nucleotides on lines 12, 16, 19, and 28 and a change in the Note to remove "calendar quarter" and replace it with the less restrictive "given time span" on lines 21 and 22. These changes are incorporated in the new page 18 attached.

To correct another error, please note that Bobby M. Wilson is still employed by the University of Louisville. Somehow, I got the impression he had left there, but he assured me in Atlanta that he had not. Remove the asterisk following his name on page 4 of the cover letter.

Respectfully submitted,

John H. Tolan

JHT/djf

"Criteria for Performing Bioassay for Tritium"
Sixth CAMPUS RSO's Conference p 275-278 300,
sponsored by the College of Health Sciences, University of Houston, Central Campus,
Houston, Texas July 11-13, 1977.

This is the revised page p.18. Page 17 was not revised but was printed so that the sheet containing the old p.18 could be discarded.

1 and other detritus of the initial handling step should also be kept within the hood. A con-
2 tainer like a one-gallon paint can with a closely-fitting lid should be provided within the
3 hood for these discards. Subsequently, the entire container with its contents will be
4 removed for disposal as solid waste.

5 Check Hood Operation

6 Before any activity is released within the hood, the health physicist must be satisfied
7 that an adequate airflow is provided for the hood. Criteria for hood performance as
8 compiled by the Scientific Apparatus Makers Association previously referenced are
9 that a Class A designation requires an average flow of 125 to 150 feet per minute with
10 corresponding minimums at any one point of 100 to 125 feet per minute. For modest
11 quantities of tritium, say in the range of 100 to 1000 mCi as HTO or equivalent in
12 other forms, a Class B designation will be sufficient. This designation requires an
13 average velocity of 100 feet per minute with a minimum at any point of 80 feet per
14 minute.

15 Recommend Conditions To Committee

16 If the health physicist has any reservations about the experiment including an
17 assessment of the qualifications of the investigator and his staff, these must be re-
18 ported to the committee to permit a proper evaluation before an authorization to pro-
19 ceed is approved. If conditions of use need to be imposed, the health physicist must
20 recommend their incorporation in the authorization. The committee may choose to
21 ignore the recommendations, but the health physicist has an obligation to make them
22 anyway. And, if the recommendations are ignored, the health physicist is obliged to
23 do his best to see that the experiment is performed successfully.

24 Perform Air Monitoring When Needed

25 For every situation in which as much as 100 mCi of tritium as HTO may escape
26 the hood, air monitoring as close to the breathing zone as possible should be performed.
27 Expressed differently, this guideline means: if the health physicist determines from
28 his evaluation of all the factors involved that there is no likelihood of as much as 100
29 mCi of tritium as HTO to escape, he will not monitor the air. Based on other criteria,
30 he may be monitoring the participants by bioassay, however.

1 Bioassay As Required

2 These guidelines are intended to supplement and complement a standard for
3 bioassay criteria being developed independently* to cover use of tritium in a more
4 general way. For the special circumstances of use in the university as described in
5 this document, there are no other guidelines extant, except those herein. To specify
6 some quantities for this preliminary draft of guidelines to be used in the university en-
7 vironment, the following criteria are anticipated to be compatible with what is recom-
8 mended for the general conditions of use:

9 Bioassays shall be performed at least monthly while tritium is in use for all individ-
10 uals exposed as follows:

- 11 1. In open-bench operations, when as much as 1 Ci of tritium as a pure gas, 100
12 mCi of tritium as HTO or as a labeled organic, or 10 mCi of tritium as a
13 nucleotide or other DNA precursor is used in uncontained form;
- 14 2. In a Class B fume hood, when more than 10 Ci but less than 100 Ci of tritium
15 as a pure gas, more than 1 Ci but less than 10 Ci of tritium as HTO or as a
16 labeled organic, or more than 100 mCi but less than 1 Ci of tritium as a nucleo-
17 tide or other DNA precursor is used in uncontained form; and
- 18 3. In a glovebox, when more than 100 Ci of tritium as a pure gas, more than 10
19 Ci of tritium as HTO or as a labeled organic, or more than 1 Ci of tritium as a
20 nucleotide or other DNA precursor is used.

21 Note: These quantities may be involved in a single, short-term experiment or they
22 may be the sum total of all tritium used within a given time span. Ten exposures
23 of 100 mCi each within the time span is counted as equivalent to a single exposure
24 of 1 Ci.

25 In the university, the criteria identified for use of tritium in a fume hood (item #2)
26 will most likely apply because almost all such uses will be performed in a hood. There-
27 fore, bioassays are not required for use in a fume hood when less than 10 Ci of tritium as
28 a pure gas, less than 1 Ci of tritium as HTO or as a labeled organic, or less than 100 mCi
29 of tritium as a nucleotide or other DNA precursor is used in uncontained form. This is
30 not to say the bioassay shall not be performed if the health physicist determines he needs
31 the information; it means only that he has an option to take or not take a bioassay under
32 these use conditions.

33 * Both the Standards Committee of the Health Physics Society and the NCRP have sub-
34 groups working on criteria for bioassay including tritium.



UNIVERSITY OF MISSOURI

This is the original report and letter of transmittal prepared before the meeting. The content was approved with a slight change in p. 18.

Radiation Safety Office

413 Clark Hall
Columbia, Missouri 65201
Telephone: (314) 882-3721

July 11, 1977

MEMORANDUM

To: University Radiation Safety Officers

Subject: Final Draft on Guidelines for Bioassay for Exposure to Tritium

At the Fifth Biennial Conference of University Radiation Safety Officers held at the University of California - Irvine in 1975, an ad hoc committee was organized to draft a set of guidelines suitable for use in the university environment to control the hazard of exposure to tritium. These guidelines were to be presented to a later meeting of the Conference for adoption, if such action was appropriate, or they were to be freely used by Conference participants on an individual basis as an information source, should the Conference deem the adoption to be inappropriate. In the two-year interval since the Irvine Meeting, nothing else has appeared to be quite so amorphous as the problem of contending with control of tritium in the university environment.

Many people continue to wonder what the discussion on tritium bioassay is all about; either their institutions do not use tritium or they are licensed by an Agreement State, which imposes no requirements. Some other people have negotiated a tritium bioassay requirement in their broad-coverage license from the Nuclear Regulatory Commission, and they are completely satisfied with this requirement. A few others are undergoing or have just completed negotiations for license renewal with the NRC, including a tritium bioassay requirement, and are incensed by the intransigence of the NRC license reviewers on the general point of licensee independence and on the particular point of use levels for which bioassays are mandatory. And a few more have completed their negotiations for renewal of their NRC licenses and have a lingering antagonism directed toward the unreasonable bureaucrats who have so distorted their programs. Finally, a small but not trivial number have a concern about the philosophical issues that are involved even though their own positions do not involve them directly in the debate. Wherever you stand, you will find company.

Since 1975, three other groups have been exploring the problems associated with monitoring personnel for exposure from radionuclides deposited within the body. One of these is a subcommittee of the Health Physics Society's Standards Committee charged with developing a standard for ANSI publication on criteria for bioassay for tritium from any source. It is appropriate that this subcommittee is concerned chiefly with chronic exposures to large quantities of tritium as in the industrial environment. The special case of relatively infrequent and acute exposure to small quantities as experienced in the university environment is supposed to be covered but may not be. Feedback from this subcommittee suggests that an unresolved determination of how much tritium of what form in what environment is unsafe is holding up the agreement necessary for publication. A

second group interested in this problem is Scientific Committee 54 of the NCRP, which is considering guidelines for monitoring of internally deposited radionuclides of any type, form, or quantity. This much broader charge touches on use of tritium in the university in only a superficial way. Lastly, the third group is the NRC's own Office of Standards Development where the Regulatory Guides are given birth. Naturally, the final product of all three groups must be compatible wherever each one impinges on another.

There is also a fourth group operating sub rosa. This group is comprised of those NRC staff members who write or impose license conditions. Without a specific reference in 10 CFR 20, without an NCRP recommendation, without an ANSI standard, and without an NRC Regulatory Guide, staff members of the Radioisotopes Licensing Branch, Division of Fuel Cycle and Material Safety, NRC, have been writing regulations without public comment in the form of license conditions. This is not an overt act on their part; it is insidious. Instead of placing their own words in the license, they insist that the licensee write a description of control methods to satisfy the reviewer and then the licensee's words are incorporated in the license by reference. When a licensee objects, he is advised he is the only one giving trouble on this matter, all other licensees with similar programs have complied, and if he doesn't capitulate, his license will be terminated. Any university radiation safety officer who has had a license renewal review within the last four years has experienced this form of ratcheting.

The draft guideline that accompanies this report is not a typical committee effort. This may be either good or bad depending on your point of view. The document grew from the substance of three reports presented at the Irvine Meeting. There was a paper by Harold Berk on action levels for bioassay, there was a paper by Orval Olson on criteria for bioassay, and there was a paper on liquid scintillation counter calibration by Jamie Shotts. The papers by Berk and Olson were distributed in September 1975 to about 50 university radiation safety officers through a regional network of committee members. Comments were solicited and comments were received.


From the comments, a first draft was prepared and forwarded in September 1976 to everyone who had commented on the original mailing plus anyone else who in the meanwhile had expressed an interest. Contact was established with the three groups previously identified, and comments were solicited from them as well. From all of these comments, a second draft was prepared and forwarded in January 1977 to the expanded list of contributors. By this time, respondents were reasonably well satisfied with the content and few additional comments were received. The final draft now in your hands represents the synthesis of comments received from dozens of people, but it in no way represents the opinion of any one of them, although it is hoped that all of them can accept this final version. No pre-meeting circulation of the final draft was made; therefore, the undersigned accepts all blame for errors of fact or of expression.

Along the way, it was hoped that the HPS group would reach some agreement on levels of exposure for which a bioassay was required. If such numbers were agreed upon, they would have been referenced in this draft with much greater confidence of their validity.

p. 3, Final Draft on Guidelines for Bioassay for Exposure to Tritium

This hoped for agreement has not been reached, so the numbers cited in this final draft have only the support of the contributors to this draft. But this is a very impressive group whose collective opinion should be persuasive. It was the intent of the contributors to this document that the effort would be consummated by a resolution of the Conference to adopt the content as its own and to support the guidelines proposed. It is offered, therefore, for such a resolution to be presented at the Sixth Biennial Conference.

Respectfully submitted,



John H. Tolan
Chairman

Acknowledgement:

The following individuals have contributed directly or indirectly to the content of these guidelines, and their contributions are hereby acknowledged:

Robert Bell, Auburn University

Harold W. Berk, Ph.D., University
of Virginia

Robert M. Boyd, Georgia Institute
of Technology

Henry C. Briggs, Indiana University

Allen Brodsky, Sc.D., U.S. Nuclear
Regulatory Commission

Leonard H. Brubaker, M.D., Univer-
sity of Missouri - Columbia

B. G. Dunavant, Ph.D., University
of Florida

William Dunnette, Mayo Clinic

E. D. Durkosh, University of Pittsburgh

John Evraets, UCLA

William J. Fields, Jr., University of
Missouri - Kansas City

Frank E. Gallagher, III, University of
California - Santa Barbara

Bruce Gillespie, The Ohio State University

J. W. Harvey, McMaster University

Robert Hight, Ph.D., University of
Missouri - St. Louis

Daniel B. Howell, Rutgers University

Stuart E. Hunt, University of Alberta

Paul R. Keenan, University of Missouri

Roger J. Kloepping, San Jose State Univer-
sity

Conrad M. Knight, Duke University

John P. Lambert, Kansas State University

Jerome B. Martin, University of Colorado*

Edward W. Mason, University of Chicago

* The asterisk indicates that the individual is no longer at the institution identified, but he was there when the contribution was made.

p. 4, Final Draft on Guidelines for Bioassay for Exposure to Tritium

S. L. Meyers, Virginia Polytechnic
Institute and State University

J. Steven Morris, Ph.D., University
of Missouri

Orval L. Olson, University of Missouri

Richard V. Osborne, Ph.D., Atomic
Energy of Canada Limited

Vincent T. Penkas, Ph.D., University
of Connecticut

Andris Peterson, University of
California - Berkeley

Eli A. Port, Northwestern University*

R. R. Radtke, The University of
Wisconsin

Jamieson G. Shotts, University of Missouri -
Columbia

Emery E. Sobottka, Iowa State University

Jerome J. Steerman, University of Illinois
at Urbana - Champaign

Daniel J. Strom, University of Connecticut*

John W. Thomas, University of Pennsylvania

Walter F. Wegst, Jr., Ph.D., California
Institute of Technology

Bobby M. Wilson, University of Louis-
ville*

And for the special encouragement that precipitated all of this effort, acknowledgement is made to Leo Wade, Jr., Ph.D., of the Radioisotopes Licensing Branch, NRC.

1 BIOASSAY FOR EXPOSURE TO TRITIUM
2 HEALTH PHYSICS EVALUATION OF NEED
3 WHY, WHERE, WHEN, AND HOW

4 WHY

5 In university laboratories, tritium is widely used in research applications related
6 to the life sciences. It is found in many forms ranging from tritiated water to labels
7 on complicated molecules. Its physical and chemical form determines how readily
8 it is exchanged and transported into the working environment, how readily it is taken
9 into the body from the working environment, and how readily it is catabolized and
10 metabolized within the body and eliminated. The control measures that are adopted
11 must incorporate a suitable consideration of the behavior of the compound at the point
12 of use. This is where and when the health physicist at the scene can be the most
13 effective in reducing the risk of exposure.

14 For reasons not entirely clear, the health physics community seems to view
15 tritium as a hazard substantially more worrisome than that posed by external sources
16 of gamma radiations. Maybe, we have become accommodated to the external sources
17 and, knowing more about their behavior, feel more relaxed and comfortable about
18 them. Certainly, the measurement is easier. Personnel monitoring for external
19 sources is also more direct and convenient, although the results leave much to be
20 desired. But, if we accept certain standards of control on the risk of exposure to
21 external sources, why should we impose more stringent standards of control on the
22 risk of exposure to internal sources?

23 If control of the compound at the point of use can be achieved and maintained, no
24 exposure to individuals will occur and a concern for a routine personnel monitoring
25 program by bioassay of urine specimens can be eliminated. We will still bioassay, but
26 we will have more confidence that the results are worthwhile. Bioassay of urine specimens
27 of individuals with a high risk of exposure to tritium must be continued, but the many
28 negative aspects of this procedure dictate a determination to keep the number at a
29 minimum. What the health physicist must do is to develop a method for urine bioassay

1 that provides adequate sensitivity, a procedure for collection that involves the least
2 commitment of manpower resources, and a procedure for evaluation of the results
3 that permits the least number of samples to assess the exposure adequately; further-
4 more, he must also control the conditions of use to minimize the number of individuals
5 being monitored.

6 Rather than concentrate attention on an assessment of the exposure after it occurs, the
7 health physicist should focus on the proposed use so that adequate control is achieved
8 and maintained before exposure can occur. To monitor the control, air sampling on a
9 grab or continuous basis should be developed where the risk of exposure is high. To
10 say with confidence that the working environment is clean and free of contamination with
11 no bioassay required is far more satisfying than to be so in doubt that bioassays are
12 needed to learn the extent of the exposure. This has been the traditional approach to
13 control of all risks of hazardous exposures to radiation.

14 To make some sense of the risk of exposure to tritium, we need an analog for the
15 internal compared to the external source. We do not want to be trapped in a situation
16 that requires essentially different evaluations of exposure. A rem of external dose is
17 supposed to be equivalent to a rem of internal dose. A maximum permissible dose
18 equivalent (MPDE) of five rem per year is supposed to apply to an internal dose or to an
19 external dose or to the sum of the two. The International Commission on Radiological
20 Protection (ICRP) has addressed this problem without a completely successful con-
21 clusion. The National Council on Radiation Protection and Measurements (NCRP) has
22 struggled with it and has not reached a general solution. In the absence of definitive
23 recommendations from either the ICRP or NCRP, the Nuclear Regulatory Commission
24 (NRC) has set control limits that bear a slight resemblance to the control limits set
25 for external sources.*

26 The ICRP has provided us with numbers to use to assess the risk of hazardous
27 exposure to tritium.† It cannot be helped, but these numbers are not applicable to the
28 typical university use of tritium. Tritium is a low-risk radionuclide partly because
29 it has a short residence time in the body, and a steady-state exposure must be main-

30 * Dramatically revised on December 29, 1976, by change of 10 CFR 20.103.

31 † ICRP Publication 2 "Permissible Dose for Internal Radiation."

1 tained to sustain a given body burden. In an industrial environment where tritium may
2 be used in a continuous or repetitive-batch process, the exposure to tritium is essential-
3 ly constant. In a nuclear power reactor, some areas of the plant will contain environ-
4 ments in which tritium is present in essentially constant concentrations. But in a
5 university environment, the exposures are more likely to be brief and intermittent. With
6 the maximum permissible body burden (MPBB) based on continuous exposure, the
7 MPBB does not adapt conveniently to the university situation.

8 For the continuous exposure conditions found in industry, it makes sense to sample
9 the working environment and the workers themselves on a regular basis. Here, con-
10 trol measures can be established to limit individual dose commitments to less than
11 five rem per year. The value corresponding to the MPDE of five rem per year
12 for tritium in the body is the MPBB of 2 mCi, as established by the ICRP. This
13 quantity, evenly distributed in the whole body with one-half of the total in the body water,
14 provides a concentration of about 29 μ Ci per liter as a steady-state value. If we per-
15 form a bioassay on an individual investigator soon after an acute exposure to tritium
16 (allowing enough time for mixing within the body) and we record a measurement of
17 30 μ Ci per liter, does this mean the MPDE is exceeded? Absolutely not! But what if we
18 measure this 30 μ Ci per liter weeks after the exposure? This is quite another matter,
19 and we need to determine the circumstances and the time of the exposure.

20 Similarly, the maximum permissible concentration for tritium in air (MPCa) is
21 based on a continuous exposure necessary to maintain the MPBB. An acute and
22 isolated exposure to the MPCa for tritium simply does not have the same significance
23 as a similar exposure to any other radionuclide with an extended residence time in the
24 body. In fact, it makes a great deal of sense to define a separate MPCa for tritium
25 to cover the acute, isolated exposure. This problem was ameliorated substantially
26 when the NRC revised §10 CFR 20.103 to permit averaging over a calendar quarter
27 instead of one week.

28 While we want to draw some comparisons between the external versus internal
29 maximum permissible doses, it is not easy to do. Such comparisons become even more
30 difficult when the same individual has a potential for exposure to both. When we have

1 reasonable assurance that only external exposure will be experienced, we survey the
2 working environment and monitor the individual with both the MPDE of five rem per
3 year and the "as low as reasonably achievable" (ALARA) concept in mind. We work
4 with the individual to modify procedures or apparatus to keep the actual dose to a
5 minimum, but we do not panic and stop the operation if a short-term dose exceeds the
6 rate of five rem per year. In fact, 10 CFR 20 provides exactly this operational
7 philosophy for external exposures.

8 The ICRP addresses this question with the concept of the Investigation Level* set
9 at such an intake as will result in a dose of one-twentieth the annual MPDE. Nothing
10 is wrong with this approach except in its application. We find that the Investigation
11 Level of 1.5 mCi intake and its corresponding body water concentration of 35 μ Ci per
12 liter is sometimes viewed as the maximum permissible amount instead of what it is
13 supposed to be - a level requiring an investigation.

14 WHERE

15 Conditions vary from one laboratory to another, and details of what can be expected
16 for each situation cannot be predicted; however, a few identifiable features are common
17 to each and can be discussed. Each proposed use has required a prior review and
18 evaluation of the form, quantity, frequency of use, and intended procedure by an
19 approval process involving the health physicist and a committee. The description of
20 the intended procedure incorporates the specifications for protective devices or apparatus
21 to be employed. After approval, each experiment can be monitored by the health physicist
22 both visually and with instruments. Each investigator can be guided or assisted by the
23 health physicist in the conduct of the part of the experiment in which the source is most
24 likely to escape control. Many contact points occur where mechanisms of control can
25 be applied.

26 Review of the Proposed Use

27 What combination of factors changes a situation from one that permits a casual
28 surveillance by the health physicist to one that requires a bioassay of a urine specimen?
29 Or, does the situation really change so dramatically without passing through one or more
30 intermediate steps? It is likely that many gradations can be defined. But if such

31 * ICRP Publication 10 "Evaluation of Radiation Doses to Body Tissues from internal
32 Contamination due to Occupational Exposure."

1 gradations are defined, do they not limit individual judgment by admitting an infinity
2 of interpretations? Nevertheless, certain quantifiable factors can be listed, placed
3 into positions of relative importance, and from them a judgment of the risk involved
4 can be made. We need to know quantity, form, frequency, and type of use. From these
5 data, we determine the ease by which the material can escape its immediate environment.
6 Note that toxicity is not considered at this point, nor are external containment systems
7 considered. These will be considered as modifying factors. For the form, we are
8 concerned initially only with whether the material will freely volatilize* or not.
9 For this type of use, what we want to know is whether the experimental system is
10 closed or open to the air and how much.

11 For a closed system with a non-volatile form, we can expect none of the material
12 will escape, and any amount within the limits we are likely to experience is safe.
13 For an open system with a volatile form, quantities less than 100 mCi are safe enough.
14 If the material can be introduced into a closed system without mishap and if we can
15 expect it to stay there, any quantity, volatile or non-volatile, is safe. But what if
16 it is spilled in transfer, or what if the apparatus leaks? Then we have an open system.
17 Do we consider a closed system as open if there is some small but finite chance of a
18 spill or a system leak? No, but we must be prepared for the consequences of a closed
19 system becoming open. In the context of deciding to bioassay or not, all we need be
20 concerned about is an open system of a volatile form containing more than 100 mCi.
21 We can assign relative risk numbers for this situation as the quantity in process in-
22 creases by uniform factors. For example, we can say we have a risk factor of one
23 for quantities less than 100 mCi, a risk factor of two for quantities between 100 and
24 1000 mCi, a risk factor of three for quantities between 1000 and 10 000 mCi, and so on.
25 All of these are for open systems with volatile compounds.

26 * Tritium used in the university environment is supplied usually in an aqueous or as
27 an alcohol solution. These may then be mixed with solvents having a higher vapor
28 pressure, but at most the relative volatility is about a factor of ten greater than water.
29 It is the vapor pressure of the compound rather than that of the solvent that is of inter-
30 est.

1 Application and interpretation of the assigned risk factors as modified by the
2 hazard-reducing properties of protective devices is what the health physicist is trained
3 to do. He analyzes the features of the proposed experiment, he considers what measures,
4 if any, are needed to reduce the risk of exposure, and he recommends to the investigator
5 those measures or adjustments determined to be necessary. Compromises may be re-
6 quired. The health physicist may not understand the experiment well enough to predict
7 what influence on its successful performance his recommendations will have if incorpo-
8 rated. It is expected that the investigator will tell him, and the health physicist will
9 propose alternatives to accomplish the equivalent result. Finally, the experiment can
10 proceed with both the investigator and the health physicist better satisfied about the
11 outcome. No one away from the scene can provide this give-and-take adjustment of
12 the parameters of the experiment.

13 Protective Devices and Apparatus

14 An open system is considered to be one for which no containment of evolving vapors
15 or gases is operating. The bottle, vial, flask, beaker, or whatever is open to the
16 atmosphere - the contents may even have spilled onto a bench top or onto the floor.
17 A volatile form of the material means that prompt exchange with room air will take
18 place by diffusion and the room will quickly fill with the material to a uniform con-
19 centration. If the room air is mechanically pumped to other locations by return flow
20 from forced-air heating or air conditioning systems, the air contamination will go with
21 it. Or, if the room has an open door, the air contamination will spread promptly to
22 adjoining spaces.

23 With an MPCa for tritium of 5×10^{-6} μ Ci per milliliter for monitored personnel,
24 a room of $4 \times 6 \times 2.5$ meters needs a source of only 0.3 mCi to provide this concen-
25 tration after complete mixing. It can be argued that MPCa values are needlessly con-
26 servative for tritium, but the point to be made here is that not much activity in the
27 source is needed when it is open to the air to produce significant concentrations. A
28 less volatile source, on the other hand, will lose some of its activity by diffusion, but
29 most of it will stay in place where it was spilled. An increase in activity as much as a
30 factor of ten must be spilled before the equivalent air concentration is achieved. A con-
31 servative-minded radiation safety program will attempt to limit such spills to the rare cat-
32 egory of an accident. The limitation will be provided by the committee approval process

1 by the expedient of denial of any application that proposed use of this or any other
2 radionuclide in quantities and for an experiment that can result in an air con-
3 centration above the MPC value. But any radiation safety program worthy of the
4 name is doing this routinely.

5 Consider the same forms of tritium in use in a fume hood. What should we con-
6 sider the protective effect of the hood to be? In the example cited above, a closed space
7 of 60 cubic meters without air exchange required only 0.3 mCi of tritium in volatile
8 form to provide the MPCa of 5×10^{-6} μ Ci per milliliter after mixing in the closed
9 space. If the tritium is spilled on the floor of a fume hood that exhausts 1.5×10^7
10 milliliters per minute (approximately 100 linear feet per minute through an opening
11 1.5×3 feet), the air in the room is exhausted and replaced every four minutes. Now,
12 just to maintain an MPCa in the exhaust duct, we need the source to volatilize
13 0.3 mCi every four minutes. If the capture efficiency of the hood is only 90-
14 percent because of random disturbances of the room air, ten times as much
15 activity must be released every four minutes to create an MPC in the room
16 air. This requires a spill or a steady leak of 3 mCi every four minutes.
17 Quantities in the less volatile forms must be correspondingly higher. Clearly,
18 the fume hood provides an environment that permits very sloppy operations
19 before much risk of exposure is evident outside of the hood.

20 With several possible pathways of entry into the body, the MPCa for tritium is
21 determined from the sum of all pathways contributing to the burden of the radionuclide
22 in the body. The obvious pathway of inhalation into the lung is mainly prevented by the
23 fume hood because common sense dictates that performance of an experiment in a
24 fume hood is accomplished with the individual's breathing apparatus kept outside. It
25 is not likely that otherwise qualified investigators will be placing their heads inside the
26 hood to examine the experiment. But they do need to place their hands and arms in-
27 side. Volatilized tritium as HTO will enter the body through the skin as readily as by
28 inhalation. This factor dictates that protective coverings impermeable to tritium be
29 worn over all of the skin exposed to the environment within the hood.

30 Unfortunately, there is almost nothing impermeable to tritium, although for short

1 periods of time there are materials that will reduce the quantity absorbed by the skin.
2 What must be done first is to limit the time that the skin is exposed by planning the
3 experiment with enough care so that hands-on adjustments are minimized. Then,
4 protective coverings like plastic, surgeon's gloves can be worn (in multiple layers if
5 necessary) to limit the skin exposure. Each thickness of the plastic provides protection
6 for only about 15 minutes, in which time the tritium has passed through to contaminate
7 the hand. What needs to be done, therefore, if prolonged operation in high concentrations
8 is required, is to wear two or three gloves and peel them off layer by layer every 15
9 minutes or so. The contaminated gloves, when removed, must be safely enclosed in a
10 tightly-covered container within the hood. Gloves that cover part or all of the forearm are
11 preferred to those that cover only the hand and wrist. Even heavy-rubber, acid-
12 resistant gloves are permeable to tritium and will become contaminated after not too
13 long a time.

14 Another mode of entry is by ingestion. For tritium as HTO, ingestion compared
15 to inhalation or absorption through the skin is of negligible concern. But for tritium
16 as a labeled organic, ingestion may be the only significant mode of entry, unless the
17 organic compound itself has a high vapor pressure. Ingestion as an intake pathway
18 is more easily controlled. We do not need to repeat the experience of the radium dial
19 painters to determine that radioactive material must not be placed in the mouth. We
20 must also insure that foods and beverages are not stored or consumed where non-
21 volatile forms of tritium are being used.

22 Altogether, we can conclude that quite substantial quantities of volatile-form
23 tritium can be handled safely in a properly functioning fume hood as long as we take
24 reasonable precautions to limit spills and wear protective covers on exposed skin.
25 Furthermore, we can conclude that even larger quantities of less volatile tritium can
26 be handled safely in a fume hood provided we take common sense measures to avoid
27 ingestion. The radiation safety program must take account of the operating characteris-
28 tics of the hood,* the precautions taken to avoid spills, the physical form of the tritium

29 * See the Scientific Apparatus Makers Association [SAMA] "Standards for Laboratory
30 Fume Hoods," LF7-1975, 1140 Connecticut Ave., N.W. Washington, D. C. 20036.

1 compound, the use and disposal of gloves, the precautions taken to avoid ingestion, and
2 the general features of the conduct of the experiment that may lead to release of con-
3 tamination.

4 Another and higher level of containment can be provided by use of a glovebox,
5 although such sophistication is rarely found in the university simply because quantities
6 of tritium for which the glovebox becomes essential are not used in the university.
7 Actually, most university-based experiments with tritium do not require even the
8 fume hood for safe handling. If required, however, by the scope of the project pro-
9 posed, the health physicist must insist that a glovebox be used or that the project
10 be scaled down to that suitable for a fume hood. Other than a consideration of scale,
11 the observations made previously about the fume hood apply as well to the glovebox.
12 Of special concern is the contamination of the gloves. After only limited use, the
13 glovebox gloves will be contaminated, and separate gloves in addition to the glovebox
14 gloves must be worn with the same attention to time limits as apply to use of gloves in
15 the fume hood.

16 Monitoring Techniques

17 Monitoring for tritium is difficult. Conventional techniques satisfactory for most
18 other radionuclides won't work. We are faced with developing special methods that
19 are far more time consuming and, hence, costly than are the methods employed for
20 all but a few of the alpha emitters that are not often found in the university environment.

21 In the non-volatile form, tritium contamination from surfaces can be picked up on
22 routine wipe samples, and the degree of contamination can be assessed provided we
23 have access to a suitable instrument to measure the low-energy beta emissions. For
24 practical purposes, this means an access to a liquid scintillation counter. Many
25 radiation safety programs have been obliged to invest the \$12-\$15,000 necessary to
26 purchase this instrument dedicated to health physics use just because access to
27 another instrument was impossible or impractical.

28 Even with the instrument available, sample preparation will require extra care
29 and some additional investment in apparatus. A budgeted radiation safety program
30 has a tendency to ignore unit costs because there is no accounting process imposed
31 upon them. Take what you have, get the job done the best way possible but don't

1 look back to analyze how you did it. In this accounting, time spent is not listed as a cost
2 factor. What does count is what you have to spend for supplies and equipment, especially
3 when requests for special appropriations must be made.

4 Tritium is extremely difficult to capture and measure. What we must do is to
5 convert the water vapor to a non-volatile form and keep it that way until the activity
6 is measured. The human body performs this operation for us by converting tritium
7 taken into the body to HTO in body water. Then, the body collects a portion of this
8 body water in the bladder and provides an on-off control so that aliquots can be
9 drawn off almost at will. In the university environment, everyone working in
10 proximity to the tritium becomes a monitor of the volatile-form tritium (and of the
11 non-volatile form also even though, as previously mentioned, non-volatile form
12 tritium does not as easily enter the body). If this monitor would stay put and be
13 conveniently accessible to obtain a sample, it would be ideal. Usually, however, when
14 the schedule for the sample comes up, our monitor has just left for New York, taking
15 his bladder with him.

16 Another way the conversion of volatile-form tritium to non-volatile form can be
17 accomplished is by duplicating in simplified form what the human body does. That is,
18 an equivalent system needs a pump to force air containing the vapor through a medium
19 like water where the vapor is condensed and trapped. A typical system* will cost
20 about \$400, and it is not subject to the damage experienced by the human body when
21 exposed to tritium. At this cost, it will not be possible to install one permanently
22 at every location where tritium is used, but the cost is not so excessive that one or
23 more cannot be obtained for placement while tritium handling is in progress. Care must

24 * For example, the system might include a Micronair pump and battery charger
25 (Baird-Atomic 952-963 @ \$340) and a micro impinger and holder (Baird-Atomic
26 952-976 @ \$44). This system has the advantage of small size for portability, freedom
27 from electrical power for flexibility, and short sampling times for convenience.

28 Another example is the use of a commercial, household-type dehumidifier modified
29 so as to empty directly into a sample bottle. With a separate measurement of the air
30 temperature and relative humidity, the quantity of the condensate can be used to cal-
31 culate the total volume of air pumped through the system. The activity in the condensate
32 divided by the volume of air pumped through will yield the average concentration of
33 HTO in the ambient air. This system is bulkier, requires an electrical power source,
34 and needs a longer sampling time.

1 be taken to sample the air at the breathing zone or between the breathing zone and the
2 source.

3 Of course, it does not matter from whence the sample came; from any source, it
4 remains necessary to have the means at hand to measure the activity in the sample
5 to a sufficient precision for assessment of the hazard. The liquid scintillation counter
6 provides enough sensitivity. Depending partially on the care taken with sample
7 preparation and instrument calibration, a minimum detectable concentration of tritium
8 can be less than 10^{-5} μ Ci per milliliter of sample. From this baseline, a modest pump-
9 ing rate through the sampling device, and a sufficient time to accumulate activity in
10 the medium chosen, the concentration of the tritium in the air should be measureable
11 down to a fraction of the MPCa*. Measure of one-percent of the MPCa is attainable.
12 Uncertainty of the method to quantify precisely the concentration of tritium in the air
13 because of the variability in the exchange rate to be expected from the water vapor is
14 not thought to be of serious concern, although methods are available to reduce the
15 uncertainties.

16 The advantage of the inanimate monitor over the animate one is that it stays in
17 place and provides its sample at the convenience of the health physicist. While some
18 sampling of the animate monitor will be necessary to establish correlation factors,
19 most one-shot, acute-exposure situations can be assessed with the inanimate monitor.
20 A program that incorporates air monitoring on a regular basis should be permitted
21 to substitute the inanimate form for the animate at low levels of exposure. This
22 substitution will not work as effectively when non-volatile-form tritium is being
23 handled. When ingestion is the only or most likely path of entry into the body,
24 monitoring with wipe samples must replace the air-sampling device.

25 Assisting the Investigator

26 The radiation safety program in the university exists to serve the investigator.
27 Indirectly, a cooperative, supportive, and professional relationship with the investi-
28 gator will also serve the university administration and the regulatory agencies, although

29 * If ten percent of the tritium is trapped upon passing through an impinger containing
30 ten milliliters of water at a flow rate of two liters per minute, the time required to
31 attain a concentration of 10^{-5} μ Ci per milliliter of the sample at the MPCa is about
32 0.1 minute.

1 these other groups may not always perceive the benefit derived. What this support
2 of the investigator means in terms of our concern with tritium is that when a special
3 problem arises, the investigator will solicit and welcome the help of the health
4 physicist in the performance of the experiment. (Imagine how easily this function can
5 be performed by an outside agency in a remote location.) Preliminary safeguards will
6 be taken, the plan of the experiment will be developed, protective devices will be made
7 ready, an emergency procedure will be devised, monitoring apparatus will be assembled,
8 and so on. A conscientious investigator can do all of these things for himself, and he
9 should if a health physicist is not available; but a prudent investigator will realize he
10 will need all the help he can get when he undertakes something new and different. When
11 the experiment becomes repetitive with all the bugs worked out, the procedure can be
12 turned over to an assistant. Whatever the risk involved in the experiment conducted
13 for the first time, it can be reduced by at least a factor of ten by having the health
14 physicist present as a participant.

15 WHEN

16 In a real sense, we are doing things backward if we sample by bioassay promptly
17 after a large exposure and much later after a small exposure. The NRC is currently
18 requiring licensees to perform a bioassay within one week of an exposure to 100 mCi
19 or more of tritium as HTO and to bioassay within one quarter of an exposure to 10 to
20 100 mCi as HTO. Setting aside for the moment the argument that these limits are too
21 small by a factor of ten, a body burden of 10 μCi derived from an exposure to 10 mCi
22 on the day after the quarter begins will be reduced to about 10^{-2} μCi after 90 days. A
23 body burden of 10 μCi will be reflected in the bioassay as a concentration of about
24 1.5×10^{-1} μCi per liter initially and about 1.5×10^{-4} μCi per liter after 90 days. The
25 initial concentration is within the sensitivity of the instrument, but the final concentration
26 is not. What do we make of this? Was the initial concentration meaningful in terms of
27 its contribution to the dose of the individual? A body burden of 10 μCi equates to a dose
28 less than two millirem - hardly worth mentioning. If even the initial quantity is
29 practically lost in the background, why sample at all for this level of exposure?
30 Provided that we have some assurance that an exposure at whatever level will result
31 in a body burden of 10 μCi or less, we should be permitted to eliminate the bioassay
32 procedure.

1 We are inclined to sample more promptly after large exposures just to reduce the
2 chance that a previous exposure did not result in an excessive dose to the individual.
3 If a body burden of 10 μCi results in a dose less than two millirem, what kind of dose
4 do we want to be concerned about? For external exposures, we monitor with film
5 badges or TLDs; and we usually investigate monthly, whole-body exposures reported
6 as 100 millirem or higher. A body burden of 600 μCi produces a dose of 100 millirem,
7 so comparatively we would want to examine every situation that resulted in a body
8 burden of 600 μCi to find out why and to correct any procedural errors producing the
9 higher dose. On the film badge (or TLD) report, we have no result for an exposure
10 reported as less than ten millirem of x or gamma radiations and 40 millirem for
11 neutrons. We do not count this as zero, but we do not attempt to assign a number to
12 it either. The body burden equivalent of ten millirem is 60 μCi of tritium.

13 If our minimum detectable concentration is 10^{-2} μCi per liter of sample and what
14 we are trying to detect is 60 μCi , we need to know how long we can wait after the
15 exposure before taking the sample. Our minimum detectable concentration equates to a
16 body burden of approximately 0.6 μCi , or about one-percent of what we are looking for.
17 This means that we have the sensitivity to detect a body burden that may have been as
18 high as 60 μCi within the past month.* On this basis, bioassay sampling more frequently
19 than once per month is wasteful, except when we know a significant exposure has been
20 received.

21 The ALARA concept embodies a cost-benefit analysis. In its recommenda-
22 tion† on ALARA, the ICRP specifically incorporates the tangible and intangible
23 factors to be considered. Different standards for internal compared to external
24 hazards are not implied. Nor are there implied any performance criteria for

25 * A factor of one hundred reduction is about seven half-lives, and with each half-
26 life being about ten days, about 70 days will pass before the body burden reduces
27 by one hundred.

28 † ICRP Publication 22 "Implications of Commission Recommendations that Doses be
29 kept as Low as Readily Achievable." Readily is changed to reasonably in the
30 conclusions.

1 personnel monitoring that suggest an internal hazard needs to be evaluated more
2 stringently than an external hazard. Even if internal doses can be measured in micro-
3 rem, the ALARA concept does not require that occupational exposures be monitored to
4 such low levels. For comparison, the instrument sensitivity previously cited of 10^{-2}
5 μCi per liter of body water is equivalent to a single intake of $0.6 \mu\text{Ci}$ which results in a
6 dose of 100 microrem. Because of the short residence time for tritium in the body, we
7 need some of the extra sensitivity to properly assess prior exposure within the sampling
8 period. We do not, however, need to look diligently for exposures at this level any more
9 than we need to be concerned about external exposures at or near natural background
10 levels.

11 What we do need is some idea of what fraction of tritium will get into the
12 body under various exposure conditions. Unfortunately, we are not even certain
13 of what fraction of the tritium in an experiment will escape the containment of the
14 fume hood to expose the body. For these transfer functions, we need much more
15 air monitoring data than are now available. The point at which the ALARA concept
16 applies in the university is when the protective devices are specified in the original design
17 of the experiment. Is a hood needed? Is a glovebox needed? What form for the tritium
18 will provide the least likelihood of intake? Should air monitoring be provided? These
19 are the questions that involve the cost-benefit analysis. Oh yes, do not forget the
20 intangible benefit to the investigator if the need to supply a urine specimen for
21 a bioassay is removed.

22 There are both tangible and intangible costs involved in a program to monitor
23 personnel by bioassay of urine specimens. Tangible costs include the time taken by
24 all parties involved, the costs of supplies, the costs of equipment and space, the
25 costs of recordkeeping, the costs of followup when required, and the miscellaneous
26 costs of instrument calibration, sample preparation, ordering and stocking of supplies,
27 and the non-productive time associated with a change in direction from one task to
28 another. Intangible costs include the nuisance factor imposed upon the investigator
29 to provide the urine specimen and to hold it for pickup. Typical values for the tangible
30 costs may be identified as follows:

31 Time: 40 minutes for the health physicist to obtain the sample.
32 10 minutes per sample to load the machine, record the results, and
33 unload the machine.

1 10 minutes per sample to prepare solutions and calibrate and
2 — maintain the machine.
3 60 minutes total time per sample. Cost for this time is about \$15
4 allowing for a modest salary, fringe benefits, and other support
5 costs.

6 Supplies: About \$2 per sample will pay for the scintillation fluid, vials, and
7 specimen bottles. (And, maybe, it will also cover the cost of getting
8 rid of the scintillation fluid.)

9 Equipment: A liquid scintillation counter costing \$15,000 initially will need to be
10 replaced every five years or so and will need maintenance in the mean-
11 while. If 1000 samples are processed each year (including wipe
12 samples), the equipment cost per sample is \$3.

13 Total cost per sample = \$20.

14 These costs are estimated on the conservative side. Some individuals will choose
15 to ignore the cost of the time because the salaries and indirect costs are budgeted
16 annually, and the cost of the equipment may be ignored because use of someone else's
17 machine is bootlegged. This leaves only a \$2 per sample cost for supplies. If only
18 50 or so samples are processed each year, merely \$100 is hardly worth worrying
19 about. On the other hand, this same program may be confronted with the requirement
20 of processing 1000 or more samples per year, and even the supplies become a cost
21 factor to be reckoned with.

22 HOW

23 What these guidelines are intending to accomplish is to provide a consistent approach
24 to the problems associated with use of tritium in the university environment and to
25 reduce the number of bioassays performed. The lower limit of this reduction is intended
26 to be the least number providing meaningful results. Each of the suggestions for
27 accomplishing these benefits is accompanied by a comment outlining the rationaliza-
28 tion for its inclusion.

29 Assure Access To a Liquid Scintillation Counter

30 This states the obvious, but it is mentioned merely because there is no point in
31 proceeding further without convenient access to this instrument being assured. As

1 mentioned earlier in the text, a sensitivity for tritium in body water (urine) of 10^{-2}
2 μCi per liter is more than enough. A calibration procedure is attached for reference
3 as Appendix A.

4 Review the Application With the Investigator

5 With due respect for the evaluations that come later, the key step of the review pro-
6 cess is the initial interview of the health physicist with the investigator. At this point,
7 the details of the project are still somewhat pliable, and one thing or another can be
8 kneaded into a form that simultaneously satisfies the investigator while still reducing
9 the scope of the health physics problems. Among the parameters to be reviewed for
10 which adjustments will be sought are:

- 11 ○ Reduce, if possible, the quantity of tritium to be handled
- 12 ○ Change the form, if possible, to that presenting the least chance of exposure
- 13 ○ Reduce, if possible, the number of individual exposures during the life of the
14 experiment
- 15 ○ Compare the experimental protocol with both the form and activity of the material
16 to seek options to reduce the risk of exposure.

17 Obtain Baseline Urine Specimen Upon Initial Application

18 At the earliest convenient opportunity after the application to use tritium is filed,
19 a urine specimen should be obtained from the investigator and from all subordinate
20 personnel likely to be exposed so that baseline concentrations can be measured and
21 recorded. Subsequently, similar baseline data should be obtained for additional
22 personnel assigned to the project. At the time of evaluation of the application, a
23 determination must be made by the health physicist whether or not sufficient tritium will
24 be handled to warrant regular or random bioassay during the life of the project. Base-
25 line specimens should not be taken from personnel for whom subsequent specimens are
26 not warranted. That is, don't clutter the files with baseline data not expected to be
27 followed by regular monitoring.

28 Contain the Activity

29 As much as possible, the health physicist should attempt to keep the activity con-
30 tained within the experimental system, and the entire system should be contained within
31 the fume hood. All discarded gloves, wipes of spills, empty vials, discharged syringes,

1 and other detritus of the initial handling step should also be kept within the hood. A con-
2 tainer like a one-gallon paint can with a closely-fitting lid should be provided within the
3 hood for these discards. Subsequently, the entire container with its contents will be
4 removed for disposal as solid waste.

5 Check Hood Operation

6 Before any activity is released within the hood, the health physicist must be satisfied
7 that an adequate airflow is provided for the hood. Criteria for hood performance as
8 compiled by the Scientific Apparatus Makers Association previously referenced are
9 that a Class A designation requires an average flow of 125 to 150 feet per minute with
10 corresponding minimums at any one point of 100 to 125 feet per minute. For modest
11 quantities of tritium, say in the range of 100 to 1000 mCi as HTO or equivalent in
12 other forms, a Class B designation will be sufficient. This designation requires an
13 average velocity of 100 feet per minute with a minimum at any point of 80 feet per
14 minute.

15 Recommend Conditions To Committee

16 If the health physicist has any reservations about the experiment including an
17 assessment of the qualifications of the investigator and his staff, these must be re-
18 ported to the committee to permit a proper evaluation before an authorization to pro-
19 ceed is approved. If conditions of use need to be imposed, the health physicist must
20 recommend their incorporation in the authorization. The committee may choose to
21 ignore the recommendations, but the health physicist has an obligation to make them
22 anyway. And, if the recommendations are ignored, the health physicist is obliged to
23 do his best to see that the experiment is performed successfully.

24 Perform Air Monitoring When Needed

25 For every situation in which as much as 100 mCi of tritium as HTO may escape
26 the hood, air monitoring as close to the breathing zone as possible should be performed.
27 Expressed differently, this guideline means: if the health physicist determines from
28 his evaluation of all the factors involved that there is no likelihood of as much as 100
29 mCi of tritium as HTO to escape, he will not monitor the air. Based on other criteria,
30 he may be monitoring the participants by bioassay, however.

This page was modified slightly during a discussion at the meeting. A revised page was then prepared and sent to all attendees.

Bioassay As Required

These guidelines are intended to supplement and complement a standard for bioassay criteria being developed independently* to cover use of tritium in a more general way. For the special circumstances of use in the university as described in this document, there are no other guidelines extant, except those herein. To specify some quantities for this preliminary draft of guidelines to be used in the university environment, the following criteria are anticipated to be compatible with what is recommended for the general conditions of use:

Bioassays shall be performed at least monthly for all individuals exposed as follows:

1. In open-bench operations, when as much as 1 Ci of tritium as a pure gas, 100 mCi of tritium as HTO or as a labeled organic, or 10 mCi of tritium as a nucleotide is used in uncontained form;
2. In a Class B fume hood, when more than 10 Ci but less than 100 Ci of tritium as a pure gas, more than 1 Ci but less than 10 Ci of tritium as HTO or as a labeled organic, or more than 100 mCi but less than 1 Ci of tritium as a nucleotide is used in uncontained form; and
3. In a glovebox, when more than 100 Ci of tritium as a pure gas, more than 10 Ci of tritium as HTO or as a labeled organic, or more than 1 Ci of tritium as a nucleotide is used.

Note: These quantities may be involved in a single, short-term experiment or they may be the sum total of all tritium used within a calendar quarter. Ten exposures of 100 mCi each within a calendar quarter is counted as equivalent to a single exposure of 1 Ci.

In the university, the criteria identified for use of tritium in a fume hood (item #2) will most likely apply because almost all such uses will be performed in a hood. Therefore, bioassays are not required for use in a fume hood when less than 10 Ci of tritium as a pure gas, less than 1 Ci of tritium as HTO or as a labeled organic, or less than 100 mCi of tritium as a nucleotide is used in uncontained form. This is not to say the bioassay shall not be performed if the health physicist determines he needs the information; it means only that he has an option to take or not take a bioassay under these use conditions.

* Both the Standards Committee of the Health Physics Society and the NCRP have subgroups working on criteria for bioassay including tritium.

1 Tritium in the pure gas form will not be encountered in the university en-
2 vironment. Sources of gaseous-form tritium that may be found are contained in
3 the metallic hydrides used in proton-beam neutron generators and in detector cells
4 for gas chromatographs. However, the gaseous-form tritium entrapped by the
5 metal hydride will oxidize immediately upon contact with room air to form HTO.
6 Consequently, the risk of exposure to gaseous-form tritium in the university environ-
7 ment can be taken to be near zero. With respect to the tritium targets for
8 neutron generators, it is worth noting that in use these targets lose a significant
9 fraction of the tritium to contamination of the equipment and especially the vacuum
10 pump oil. Care must be taken, therefore, when targets are changed or other
11 maintenance operations are performed to avoid a needless exposure.

12 Non-routine Bioassay

13 In the university under normal use conditions, investigators employing tritium in
14 their experiments will not be using it on a regular basis or using quantities that will
15 require a regular bioassay sampling. The health physicist will want to be satisfied
16 that no significant intakes are experienced. For this purpose, the health physicist will
17 be surveying the laboratory on a regular schedule, and the tritium use rate will be noted
18 as part of the inspection protocol. Periodically, individuals from such a laboratory
19 should be invited to submit urine specimens for bioassay the results of which will serve
20 as a supplement to the survey results. Because the likelihood of a significant uptake
21 is small for this situation, the bioassay should be performed soon after the exposure
22 but not necessarily after each exposure. To accumulate the highly desired transfer
23 function relating exposure to intake, notes on the circumstances of the exposure should
24 be recorded.

25 Evaluation

26 With a sensitivity for detecting tritium in the urine of about $10^{-2} \mu\text{Ci}$ per liter
27 by this method, there is much more sensitivity available than required to detect
28 significant concentrations. In a university, where monitoring by bioassay of urine
29 specimens is directed to detecting single, isolated, acute uptakes, the ICRP
30 Investigation Level is what we want to detect. This single intake of 1.5 mCi pro-

1 duces a tritium concentration in the urine of 35 μ Ci per liter. If we are sampling
2 monthly, an initial concentration of 35 μ Ci per liter can be reduced to about 5 μ Ci
3 per liter at the time the sample is taken if the intake occurred at the beginning of
4 the month. We are, therefore, interested in exposures that result in urine con-
5 centrations of the order of 1 μ Ci per liter, and we have more than enough sensitivity
6 for that.

7 Should there be a condition in the university laboratory of a chronic rather than
8 an acute exposure, the ICRP Derived Investigation Level* provides a method by which
9 the total intake averaged over a number of days can be correlated with the Investigation
10 Level based on an acute uptake. That is, if the quantity of 1.5 mCi is actually acquired
11 over a time of ten days, the uptake per day is 0.15 mCi and the body burden at the
12 end of the ten days is just above one mCi. Concentration of tritium in the urine at
13 that time is proportional to remaining activity rather than the total uptake.

* ICRP Publication 10A "The Assessment of Internal Contamination Resulting from Recurrent or Prolonged Uptakes."

1 APPENDIX A

2 TECHNIQUE FOR BIOASSAY FOR TRITIUM IN URINE*

3 Preliminary Steps

- 4 1. A counting standard is prepared from a known activity of tritiated water to
5 yield a concentration of about 1 nCi per milliliter. The actual concentration
6 must be known and be traceable to an NBS Standard, but the known value can
7 be more or less than 1 nCi per milliliter. With provisions for containment†
8 of the HTO vapors, a quantity of this counting standard can be prepared at one
9 time sufficient to last several months.
- 10 2. A "background urine" vial is prepared with one milliliter of uncontaminated
11 urine and ten milliliters of scintillation fluid, and the contents are sealed to
12 serve as the perpetual source for the background count to be taken with each
13 sample.
- 14 3. An operational check is performed on the instrument to insure its proper
15 condition for use.

16 Procedure

- 17 1. A urine specimen is collected in a disposable specimen container of about eight
18 fluid ounces capacity.
- 19 2. Three each, low-background, glass vials are prepared with ten milliliters of
20 scintillation fluid. The vials are labeled "a," "b," and "c." (Other labels
21 of choice may be substituted by those preferring something more exotic.)
- 22 3. One milliliter of the urine specimen is added to each of the "b" and "c" vials.
- 23 4. One milliliter of the counting standard is added to each of the "a" and "b" vials.
- 24 5. The "a" vial is counted to insure that the instrument is adjusted properly to
25 respond to the expected count rate of the standard.

26 * This procedure is utilized by the Health Physics Services, University of Missouri-
27 Columbia, and has been found to be convenient and reliable for the assessment of
28 tritium concentration in urine specimens.

29 † Containment should be glass rather than plastic as otherwise some of the tritium
30 will escape through the wall. See "Loss of ¹⁴C and ³H from Liquid Scintillation Count-
31 ing Vials," reported by Joseph L. Thompson and David A. Olehy in the May 1977 issue
32 of Environmental Science & Technology, pp. 513-4.

- 1 6. The "background urine" vial and the "b" and "c" vials are counted for ten
2 minutes each.
- 3 7. Net count rates "B" and "C" are determined by subtracting the count rate
4 obtained for the "background urine" vial from the count rates measured for the
5 "b" and "c" vials.
- 6 8. Tritium activity is calculated by the equation:

7
$$TA = \frac{S \times C \times 10^3}{(B - C) \times 2.22 \times 10^6} \mu\text{Ci per liter,}$$

8 where S = activity in one milliliter of the counting standard expressed in
9 disintegrations per minute,

10 B = net counts per minute of "b" vial, and

11 C = net counts per minute of "c" vial.

12 Having urine in both the "b" and "c" vials automatically cancels the quenching
13 effect of the urine.